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The primary aim of the study was to investigate possible mechanisms behind the improved arterial 
oxygenation in ventilator-treated patients with acute lung injury (ALI) or acute respiratory distress 
syndrome (ARDS) when turned into prone position. A secondary aim was to discover new knowl-
edge of possible importance for treatment of patients with oxygenation problems in intensive care 
and during anesthesia. 
Previous work have described a dominant blood flow in dorsal lung regions regardless of posture 
and a better matching of ventilation (V) and perfusion (Q) in prone vs supine posture. Perfusion 
and also V/Q ratios are more homogeneous in prone than in supine position. The hypothesis of the 
study was that differences in regional pulmonary vasoreactivity to the endogenous vasodilators 
nitric oxide (NO) and prostacyclin (PGI2) may explain the improved gas exchange in severe lung 
disease during ventilator treatment in prone position. 
Regional pulmonary vasoreactivity to NO and PGI2, as well as effects of posture on distribution of 
regional pulmonary blood flow, were investigated in isolated human and porcine lung tissue and 
pulmonary arteries in vitro and in volunteers and patients in vivo. 
Presently it was shown that expression of mRNA for endothelial NO synthase (eNOS) was higher 
in dorsal compared to ventral human lung regions. Ca2+-dependent NOS activity was higher in 
dorsal than in ventral regions of both human and porcine lungs. Relaxation of porcine pulmonary 
arteries in vitro by acetylcholine and bradykinin, endothelial-dependent vasodilators, acting via 
the NO / cGMP pathway was more potent in vessels from dorsal than from ventral lung regions. 
Furthermore, NOS inhibition by infusion of NG-monomethyl-L-arginine (L-NMMA) redistributed 
blood flow from dorsal to ventral lung regions in healthy volunteers in supine position. Altogether 
these results strongly suggest a role for endogenous NO in regulation of regional pulmonary per-
fusion. 
Inhalation of iloprost, a synthetic PGI2 analogue, decreased arterial oxygen tension in healthy vol-
unteers. Pulmonary perfusion was redistributed towards dependent lung regions in both supine and 
prone, whereas ventilation was redirected towards non-dependent lung regions in supine position, 
indicating increased mismatch of ventilation and perfusion. Prostaglandin synthesis inhibition by 
the non-selective cyclooxygenase (COX) inhibitor diclofenac did not affect pulmonary perfusion 
distribution or oxygenation in healthy subjects. 
Patients subjected to left side thoracic surgery in lateral decubitus position with one-lung venti-
lation (OLV) were treated with non-selective COX-inhibition by diclofenac infusion. They had 
significantly lower shunt and better oxygenation as measured by alveolo-arterial oxygen difference 
than patients receiving placebo. The results suggest that a COX-related arachidonic acid metabolite 
attenuates pulmonary hypoxic vasoconstriction. 
In conclusion the results strongly suggest a role for endogenous NO in regulation of regional pul-
monary perfusion. PGI2 is likely not involved in regulation of regional pulmonary perfusion during 
normoxia whereas it may be of importance during hypoxia. The present results may become of 
importance for patients with oxygenation problems in intensive care as well as during one-lung 
ventilation for thoracic surgery.  
Keywords: Regional pulmonary perfusion, nitric oxide, prostacyclin, NOS-inhibition, COX-inhibi-
tion, shunt, one-lung ventilation.
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AbstrAct (swe) 
Huvudsyftet med aktuell avhandling var att undersöka vilka mekanismer i lungorna som ligger 
bakom den förbättrade syresättningen av blodet hos svårt lungsjuka respiratorbehandlade patienter 
när de vänds i bukläge. Ett andra syfte var att söka efter ny kunskap som skulle kunna vara av be-
tydelse för patienter med syrebrist inom intensivvård och under operationer. 
Tidigare forskning har visat att en dominerande del av lungblodflödet går till ryggnära lungdelar 
oavsett kroppsposition, dvs. både i rygg- och bukläge. Anpassningen mellan luft- och blodflöde har 
också visats vara mer optimal i bukläge. D.v.s. blodet går i större utsträckning till lungdelar där 
det finns gott om syre. Hypotesen i studien var att de kroppsegna blodkärlsvidgande ämnena kväve 
monoxid (NO) och prostacyklin (PGI2) kunde förklara den förbättrade syresättningen av blodet i 
lungorna vid svår lungsjukdom under respiratorbehandling i bukläge. 
Avhandlingen beskriver studier av reglering av regionalt lungblodflöde av de två ämnena NO och 
prostacyklin PGI2, som båda bildas i de celler som täcker insidan av kroppens blodkärl (endotelcel-
ler). Effekter på blodflödets fördelning i lungorna beroende på kroppsläge (rygg-, buk- och sido-
läge) undersöktes också. 
Det visades att genetisk information (mRNA) för proteinet som bildar NO i endotelceller, endoteli-
alt NO syntas (eNOS) fanns i större koncentration i ryggnära lungregioner. Calcium-beroende NO 
syntas som finns i kärlendotel och nervceller hade högre aktivitet i ryggnära lungdelar än bröstnära 
hos både människa och gris. Vid hämning av NO-bildning via blockering av NO-syntas omfördela-
des lungblodflödet i ryggläge hos friska försökspersoner från ryggnära till bröstnära lungregioner. 
Undersökning av isolerade kärl i så kallade organbad visade även större kärlvidgning i de ryggnära 
kärlen jämfört med de bröstkorgsnära när de stimulerades med ämnen som verkar via NO. Detta 
talar för att NO bildat i lungorna har betydelse för regleringen av regionalt lungblodflöde. 
Inandning av syntetiskt prostacyklin sänkte syrehalten i blodet på friska försökspersoner. (Hos 
lungsjuka brukar vanligen blodets syrehalt stiga.) Lungblodflödet omfördelades mot lågt liggande 
lungregioner både i rygg- och bukläge, d.v.s. effekten av gravitationen förstärktes. Luftflödet om-
fördelades i ryggläge mot högt liggande lungdelar, dvs. i motsatt riktning mot blodflödet, vilket 
skulle kunna leda till försämrad matchning av blod och luftflöde och därmed bidra till den sänkta 
syrehalten i blodet hos lungfriska. Hämning av bildning av kroppsegna prostaglandiner (tex. pro-
stacyklin) med en cyclooxygenashämmare (diklofenak) påverkade inte blodflödesfördelning eller 
syresättning hos friska. 
Patienter som opererades i vänster lunga med ventilation av endast den icke-opererade lungan (en-
lungs ventilation) fick förbättrad lungblodflödesfördelning vid behandling med diklofenak jämfört 
med patienter som fick icke verksam behandling (koksalt). Vid avstängning av en lunga uppstår 
syrebrist i denna och blodet styrs då över till den luftfyllda lungan för att blodets syresättning ska 
bli så effektiv som möjligt (syrebrist-utlöst kärlsammandragning). Våra resultat tyder på att denna 
kroppsegna skyddsreflex förstärktes pga hämning av en prostaglandinlik substans (t.ex. prosta-
cyklin) som motverkar den syrebristutlösta kärlsammandragningen. 
Sammanfattningsvis tyder resultaten på att kroppseget NO har betydelse för reglering av regionalt 
lungblodflöde. Kroppseget prostacyklin är sannolikt inte inblandat i reglering av regionalt lung-
blodflöde hos friska med normal syrehalt i lungorna medan det kan ha betydelse vid syrebrist. 
Resultaten kan ge uppslag till nya behandlingsalternativ för patienter med syrebrist inom intensiv-
vård samt vid operationer med enlungs ventilation. 
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Abbreviation index
AbbreviAtion index
ALI  Acute Lung Injury
ARDS  Acute Respiratory Distress Syndrome
CI  cardiac index (=cardiac output/body surface)
CMV  controlled mechanical ventilation
EELV  end-expiratory lung volume (=FRC)
FIO2  inspired fraction of oxygen
FRC  functional residual capacity
HPV  hypoxic pulmonary vasoconstriction
L-NMMA  NG-monomethyl-L-arginine 
NO  nitric oxide
NOS  nitric oxide synthase
NSAID  non steroidal anti-inflammatory drugs 
PASMC  pulmonary arterial smooth muscle cells
P (A-a) O2  alveolo-arterial oxygen tension difference
PaO2  arterial oxygen tension
PaCO2  arterial carbon dioxide tension
PaO2 / FIO2  arterial oxygen tension/inspired fraction of oxygen
PBF  pulmonary blood flow
PEEP  positive end-expiratory pressure
PGI2  prostacyclin
PVR  pulmonary vascular resistance
Q  lung perfusion
SPECT  single photon emission computed tomography
SvO2  mixed venous oxygen saturation 
TLC  total lung capacity 
V  ventilation
V/Q  ventilation perfusion ratio
Pressure units conversion formula: 101.3 kPa = 760 mm Hg (Torr) = 1 atm.
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introduction
During the last half-century a striking development has occurred within the medical and technical 
fields of Intensive Care Medicine. Despite increased possibilities to provide more advanced and 
gentle mechanical ventilatory support 146, mortality is still high, between 30 and 50%, for patients 
subjected to ALI or ARDS 19, 76, 86, 91, 121. The substantial number of patients dying from hypoxia in 
spite of adequate cardiac function strongly marks the need of increased knowledge in pulmonary 
pathophysiology. Continued research about mechanisms governing gas exchange is required. 
Extracorporeal oxygenation offers an ultimate therapeutic strategy. It is an advanced rescue therapy 
which is, due to high costs limited to a small number of patients, especially in times of economi-
cal strain. However, early initiated position treatment is cost effective and feasible even in smaller 
Intensive Care Units, and has been shown to improve arterial oxygenation 5, 24, 39, 100, in 65-75 % of 
the patients turned into prone position 28, 50, 57, 73, 87, 112, 159. In spite of the improvement in oxygenation 
no randomized clinical trials have shown improved survival by ventilator treatment in the prone 
position. Post hoc analysis of subgroups suggest that mortality may be reduced in patients with se-
vere ARDS and there is also a tendency towards lower mortality when prone position treatment is 
initiated early 50, 87, 137, 160. Nevertheless, the question still remains concerning the causative mecha-
nisms behind the improved oxygenation. During the last decades there has been a consistency in 
literature that prone position provides a more homogenous ventilation and perfusion ratio 7, 99, 129. 
But why are perfusion and ventilation distributions better matched in the prone position? Suggested 
mechanisms are increased FRC 113, decreased vertical pleural pressure gradient 102, 147 a more evenly 
distributed lung tissue due to less compression by the mediastinal and abdominal structures 4, 118, 124, 
more homogenous regional ventilation/perfusion ratios due to basic vascular anatomical structure 
7, 52, 55 and higher vascular conductance in dorsocaudal lung regions 14, recruitment of dorsal atelec-
tatic lung units 81, regional changes in ventilation due to alterations in chest wall mechanics 23, 112 or 
increased secretion drainage in the prone position. Enhanced understanding, how to optimize the 
complex ventilation / perfusion matching in the lung, might extend the treatment strategies for the 
clinicians challenged by severe hypoxic patients. 
This thesis will chiefly discuss mechanisms regulating blood flow distribution in the lung, with 
special reference to vasoreactivity and posture. Distribution of ventilation and V/Q-ratios will not 
be discussed in detail.
General pulmonary perfusion 
The lung possesses a low resistance circulation that must, at all times, accommodate the entire 
cardiac output. Moreover, to ensure adequate oxygenation of haemoglobin, blood flow must be 
directed to well-ventilated lung units, i.e., ventilation and perfusion must be matched 48. One re-
markable characteristic of the low pressure pulmonary circuit is its capacity to decrease pulmonary 
vascular resistance (PVR) as pressure within the system rises. Two mechanisms are responsible 
for this: recruitment and distension of vessels. Another unique feature of the pulmonary circula-
tion is that vessels are exposed to different distending forces as lung volumes expand and diminish 
above and below functional residual capacity. As a result, the diameter and length of the vessels 
are passively influenced by changes in lung volume, at the same time as there are numerous active 
Introduction
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neurogenic, chemical and humoral factors governing the vascular diameter 48.Total lung blood flow 
is also influenced by the cardiac function and changes in pulmonary blood volume. 
All interrelated mechanical and chemical factors governing pulmonary blood flow contribute to 
the complexity of pulmonary physiology and challenge the clinician to make the right decisions to 
optimize ventilation / perfusion matching. When comparing investigations concerning distribution 
of pulmonary blood flow, there are many factors in a study design that may influence the results. 
For instance, spontaneous breathing versus positive pressure ventilation; awake subjects versus 
anesthetized with muscular relaxation; in vitro versus in vivo conditions will all have great impact 
on the pulmonary perfusion (and ventilation) distribution 17, 48, 64, 145, 148.
Regional pulmonary perfusion.
The distribution of pulmonary blood flow is chiefly governed by the distensibility of vessels and 
their transmural distending pressure 48. It is now apparent that although gravity does have a meas-
urable influence on pulmonary blood flow (PBF) distribution, the anatomic structure of the arterial 
tree plays a prominent role in the distribution of PBF 49, 52, 55, 66, which will be discussed below. 
Since the 1960´s, when West introduced the zonal model based on the relationship between pul-
monary arterial, alveolar and venous pressures, gravity has been considered the predominant factor 
for regional pulmonary perfusion and ventilation distribution. Studies using radioactive gases and 
external scintillation counters on isolated, perfused, animal lungs showed a greater regional blood 
flow to the dependent (bottom) regions 125, 162. Later investigations on humans confirmed these find-
ings, and gravity was considered as the most important determinant of lung blood flow distribution 
84. Recent research, however, with high resolution technology using fluorescent microspheres, has 
shown considerable blood flow heterogeneity within iso-gravitational planes 51, 52, 53, 65, 155, findings 
that cannot be explained by the zonal model based on the influence of gravity. In animal studies 
Glenny et al used the redistribution of pulmonary blood flow at a change in posture to demonstrate 
that the effect of gravity is minor in proportion to overall variation in regional blood flow 53. Later, 
SPECT investigations of pulmonary ventilation and perfusion in humans have confirmed that grav-
ity is of less importance in the prone and supine positions, but has greater influence in the upright 
position 7, 119. In microgravity environment, i.e. space experiments, the blood flow heterogeneity 
remains which confirm that gravity is a minor determinant of regional lung blood flow distribution 
54, 123. During hypergravity conditions at 5G, on the other hand, there is a redistribution of blood 
flow in opposite direction to the gravitational force 117. Altogether, these results have lead to the 
challenging assumption that the basic anatomical structure of the pulmonary vascular tree is an 
important determinant of regional blood flow 66. 
In 1986, Beck and Rehder demonstrated regional differences in vascular conductance in isolated 
dog lungs 14, which raised the postulate that there might exist differences in regional vasoreactiv-
ity in the lung. This hypothesis was further strengthened by a study by Pelletier et al., 1998, which 
showed differences in vasoreactivity to various vasorelaxing agents in isolated dorsal and ventral 
equine pulmonary arterial rings 111. 
In 1946, Euler showed that regional hypoxia could divert pulmonary blood flow away from poor-
ly ventilated lung units with inadequate oxygenation to better ventilated regions 163. This unique 
behaviour to hypoxia in the pulmonary vessels, called the hypoxic pulmonary vasoconstriction 
(HPV), provides an important mechanism for maintaining optimal ventilation / perfusion match-
ing and improves arterial oxygenation 18, 90, 161. There are numerous local vasoactive substances that 
modulate HPV 46, 138 and thereby play an indirect role for regulation of regional pulmonary blood 
flow. Posture may also affect blood flow diversion by HPV 154. If there exist regional differences in 
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sensitivity to hypoxia in the lungs has to be further investigated in this work. In this thesis we have 
focused on vasorelaxing substances acting via the NO /cGMP or the PGI2 /cAMP pathways.
Pulmonary vasoregulation
The pulmonary circulation is unique in that it must, at all times, accept the entire cardiac output and 
yet, despite large and variable blood flows, direct the blood flow to well-oxygenated regions. Thus, 
the regulation of pulmonary vascular tone is complex with a balance between local vasoconstrict-
ing factors directing blood flow to well-oxygenated lung units and on the other hand, vasorelaxing 
factors that must maintain a low resistance in the pulmonary circuit to protect the right ventricle 
that cannot tolerate a high after-load. The pulmonary vascular resistance (PVR) is normally kept at 
approximately one-tenth of the systemic vascular resistance. 
Changes in PVR can be caused by 
active or passive factors 11. Active 
changes are accomplished by neu-
rogenic, chemical and humoral fac-
tors, while passive changes in PVR 
imply alteration in vessel calibre in 
response to factors such as lung me-
chanics or hemodynamics (where 
posture, gravity and vascular struc-
ture play a role). Some of these fac-
tors are listed in (table 1) 48. 
Active forces alter PVR and tone, 
and hence the distribution
of pulmonary blood flow, by causing 
contraction or relaxation of vascu-
lar smooth muscle 11. An increase in 
tone will occur if any of these factors 
directly or indirectly increases the cytosolic Ca2+-concentration to more than 10-6 mol l-1.
Ca2+-ions then bind to calmodulin (CaCM) 
a) which activates myosin light chain kinase (MLCK). The active 4Ca2+-CM-MLCK complex 
phosphorylates myosin and enables interaction with actin leading to muscle contraction. 
b) bind to caldesmon, which then detaches from the actin tropomyosin complex, thus making it 
available for filament sliding. 
Direct phosphorylation of caldesmon by protein kinase C also seems to induce filament sliding 
and contraction. 
On the other hand, factors causing a decrease in intracellular Ca2+-concentration to less than 10-6 
mol l-1 or activates phophatase induce relaxation. Also, direct activation of protein kinase C  stimu-
lates myosin light chain kinase which then phosphorylates myosin regulatory light chain  leading 
to Ca2+ -desensitization of myofilament and thereby relaxation of the smooth muscle.
Increased cytosolic levels of cGMP or cAMP is one of the major mechanisms mediating vasodila-
tion under physiologic conditions. cGMP mediates the action of endogenous vasodilators such as 
NO, carbon monoxide (CO) and natriuretic peptides 151 via inhibition of phosphodiesterases, acti-
vation of soluble and membrane bound guanylyl cyclase. An increase in cGMP activates protein 
kinase G, leading to decrease in cytosolic Ca2+-concentration via uptake in the sarcoplasmatic re-
Introduction
Table 1. Factors that alter Pulmonary Vascular Resistance  
Inreased PVR   Decreased PVR  
Active
 
Sympathetic stimulation Nitric oxide
Hypoxia Prostaglandins ( PGI2,PGE2)
Hypercapnia Acetylcholin
Acidosis Bradykinin
Catecholamines Isoproterenol
Angiotensin II Theophylline
Endotelin-I Phosphodiesteras inhibitors
Histamin (H1)
Prostaglandins (D2,E2,F2,)
Substance P
Leukotrienes
Seretonin
Passive
Lung inflation or deflation from FRC Increased cardiac output
Increased perivascular pressure Increased Ppa and Pla
Increased blood viscosity Increased pulmonary blood volume
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ticulum and inhibition of voltage-operated calcium channels (VOCC) and thereby causes relaxation. 
cAMP activates protein kinase A, which inhibits phospolipase C and VOCC, stimulates Ca2+ uptake 
in the sarcoplasmatic reticulum and thereby decrease cytosolic Ca2+-concentration leading to relaxa-
tion95. Furthermore cAMP and cGMP reduces myofilament Ca2+ -sensitivity (Fig.1). 
For the most part, vasoactive substances have similar effects on pulmonary and systemic vessels. 
However, there are some important exceptions; hypoxia, hypercapnia and acidosis produce vasodila-
tation in the systemic circuit whereas these factors produce vasoconstriction in the pulmonary cir-
culation. One primary physiological determinant of vascular resistance in lung is alveolar pO2 
61, 98. 
The unique behaviour of the pulmonary vascular smooth muscle cells in response to hypoxia is an 
Figure 1 Schematic overview of the proposed mechanisms for a) vasorelaxation mediated by the 
endothelium dependent eNOS / NO / guanylate cyclase/ cGMP and COX / prostacyclin / adenylate cyclase 
/ cAMP pathways. b) pulmonary vasoconstriction induced by hypoxia.
For details see text page 15. Plus sign = stimulation; minus sign = inhibition, question mark = not 
established.
Ach = acetylcholine, Bk = bradykinin, NO = nitric oxide, eNOS = endothelial nitric oxide synthase, PGI2 
= prostacyclin, NADPH = dihydro-nicotinamid-adenine-dinucleotide phosphate, PKG = protein kinase 
G, PKA = protein kinase A, PKC = protein kinase C, SR = sarcoplasmic reticulum, ATP = adenosine 5´-
triphosphate, cAMP = cyclic adenosine- 3´, 5´-monophosphate, GTP = guanosine 5´-triphosphate, cGMP 
= cyclic guanosine 3´, 5´-monophosphate, IP3= inositol 1´4´5´-triphosphate, PASMC = pulmonary arterial 
smooth muscle cells
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The unique behaviour of the pulmonary vascular smooth muscle cells in response to hypoxia is an 
adaptive vasomotor response of resistance pulmonary arteries, aimed to divert blood from poorly 
oxygenated areas to better ventilated lung segments thus improving ventilation-perfusion matching 
and thereby reducing shunt fraction and optimizing PaO2 
88, 144, 163,. HPV is intrinsic to the lung and, 
although modulated by the endothelium, the core mechanism is in the smooth muscle cells. The 
exact mechanism for HPV is still elusive 161. The Redox Theory proposes that HPV results from 
a coordinated action of a redox-based sensor (proximal mitochondrial electron transport chain) 
which generates a diffusible mediator, a reactive O2 species (ROS) that regulates effector proteins. 
Hypoxic modulation of ROS leads to inhibition of the specific O2-sensitive voltage-gated potas-
sium channels (Kv1.5 and Kv2.1), leading to depolarization of pulmonary artery smooth muscle 
cells, activation of L-type voltage-gated calcium channels, which increases calcium influx and 
initiates vasoconstriction 93, 98, 127. The exact time course of HPV is still under debate in the lit-
erature. However, the onset of HPV is immediate (in seconds), seems to be biphasic with a first 
endothelium independent culmination in 10-15 minutes and then a second endothelium dependent 
increase after 30-40 minutes 88, 98 with sustained, or even increased effect for hours 72, 142 or until 
reoxygenation occurs 36. The sustained response seems to be endothelium dependent and is thus 
subjected to modulation by endothelium derived vasoactive substances. Vasorelaxing substances 
like nitric oxide and prostacyclin have been shown to decrease the HPV response via mechanisms 
not fully known 46, 138.
The principal stimulus for HPV is alveolar hypoxia, whereas decreased mixed venous oxygen ten-
sion is only a contributory factor. Marshall and Marshall 1980 showed that the magnitude of blood 
flow diversion is related to the size of the hypoxic lung segment 88. If the hypoxic part equals one 
lung, for instance during one-lung ventilation, numerous clinical studies have found that shunt in 
the non-ventilated lung is usually 20-25% of the cardiac output as opposed to the 40-60% shunt that 
might be expected if there was no HPV 17, 18. In case of global hypoxia, there will be an increase in 
pulmonary arterial pressure due to general vasoconstriction, instead of PBF diversion. 17, 18, 88, 148. 
There has also been demonstrated heterogenicity in HPV response in porcine lungs which partly 
may explain high-altitude pulmonary oedema 67. 
In the present thesis we have focused on the potent pulmonary vasodilators nitric oxide and pros-
taglandin I2 to investigate their role in regulation of regional pulmonary perfusion, during both 
normoxia and hypoxia. The influence of posture on regional perfusion distribution has also been a 
subject of our interest. By altering posture there will be a change in PVR due to influence of passive 
mechanical factors, as discussed earlier, which might interact with the effects of local vasoactive 
substances. It is difficult to identify the precise contribution of each of these factors to regulation of 
regional pulmonary blood flow. They are often interrelated, so a change in one affects a change in 
another; which adds to the complexity of pulmonary pathophysiological research. 
Nitric oxide (NO) 
 
In 1980, Furchgott and Zawadzki observed that intact endothelium was mandatory for induction of 
arterial relaxation by acetylcholine 47. This endothelium-dependent vasorelaxation was later shown 
to be due to production of NO 71. NO is produced by oxidation of L-arginine to citrulline, catalyzed 
by the enzyme NO-synthase (NOS) 110. NO-synthase exists in three isoforms; two Ca2+ and calmod-
ulin requiring constitutive enzymes found in neural tissue (nNOS) and in vascular endothelial cells 
(eNOS), and a Ca2+-independent inducible enzyme (iNOS) isolated from macrophages, vascular 
smooth muscle cells and neutrophiles 157. NO can also be produced non-enzymatically by direct 
reduction of nitrite during acidotic or ischemic conditions 164.
Introduction
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Substances like acetylcholine and bradykinin cause an increase of intracellular free calcium con-
centration in the endothelium activating NOS and stimulating NO production 62, 85. NOS is only 
modestly expressed in the pulmonary vessels in normal lung, suggesting a limited role in maintain-
ing low basal tone 40. However, it is markedly up regulated in response to hypoxia or inflammation, 
thus playing a central role in modulating the response to pulmonary vasoconstrictor stimuli such as 
hypoxia 62 and to local vasoconstrictors like angiotensin-II, endothelin-I or thromboxane A2 (TXA2) 
115, 136. Increased vascular shear stress 120 and mechanical factors like stretching 116 are also known 
to be potent stimuli for endothelial NO synthesis. 
NO is a potent pulmonary vasodilator, relaxing precapillary resistance vessels to a greater degree 
than the large capacitance vessels 44. It diffuses freely over the cell membrane, activates guanylyl 
cyclase leading to increased levels of cGMP and thereby a decrease in intracellular free calcium 
concentration in the pulmonary vascular smooth muscle cell and thus vasorelaxation 34, 96, 149. NO is 
short-lived with a biological half-life of 2 – 30 seconds. It rapidly and avidly binds to haemoglobin 
and forms nitrosylhemoglobin and methemoglobin 32. NO binds to and is inactivated by haemo-
globin before it can reach the systemic circulation, which makes it suitable as a selective pulmo-
nary vasodilator when inhaled 46. NO synthesis can be blocked by using competitive inhibitors to 
the substrate L-arginine which binds to a specific site on the activated NO-synthase 96, 68. 
Besides regulation of vascular tone, NO is involved in a variety of biological processes. In the 
lung, NOS is expressed in airway epithelial cells, in macrophages, mastcells, neutrophiles, smooth 
muscle cells, fibroblasts and platelets 56, 141. 
Prostaglandin I2 (PGI2)
Prostacyclin is one among a number of prostaglandins synthesised in the lung. Prostaglandins, a 
group of the eicosanoid family, have an important role in regulation of pulmonary vascular and 
bronchial tone. They also have important anti-inflammatory actions and modify platelet aggregation 
63, 75. The prostaglandins are derived from the cyclooxygenase (COX) metabolism of arachidonic 
acid, a component of membrane phospholipids 156. There are two isoforms of the enzyme cycloox-
ygenase, COX-I being constitutively expressed, and COX-2, which is induced in inflammatory 
processes 63, 132. The various prostaglandins have potent, often opposing actions in the pulmonary 
vasculature and airways, for instance PGD2, PGE2 and PGF2α as well as TXA2 elicit vasoconstric-
tion, while PGI2 (prostacyclin) and PGE1 cause vasodilation 
75. The most important pulmonary cell 
type responsible for the synthesis of cyclooxygenase products is the vascular endothelial cell, and 
the preferentially synthesised product is prostacyclin. Prostacyclin is a potent pulmonary vasodila-
tor with a half-life of 4 minutes, and biological effect of 20-30 minutes. It acts via stimulation of 
the adenylyl cyclase / cAMP pathway, thus decreasing the intra-cellular calcium concentration and 
thereby initiating vasorelaxation. Prostacyclin is metabolised by beta-oxidation in the liver 63, 132. 
PGI2 production can be up regulated via increases in blood flow, shear stress 
45, 131 and hypoxia 60.
Aspirin and non-steroidal anti inflammatory drugs (NSAIDs) are analgesic and anti-inflammatory 
by virtue of inhibition of the cyclooxygenase mediated biosynthesis of prostaglandins. The efficacy 
and selectivity of the COX-inhibiting effect depends on dose and drug properties. Among the non-
selective COX-inhibitors, indomethacin and ipobrufen inhibit both the synthesis of prostacyclin 
and TXA2, while diclofenac seems to have less effect on the TXA2 synthesis 
27. 
As compared with nitric oxide, prostacyclin has a variety of effects in the lung. Besides modulation 
of vascular tone, prostacyclin inhibits platelet aggregation and smooth muscle cell proliferation, 
effects that can be of importance in treatment of pulmonary hypertension 105, 107,69.
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Posture
During the latest two decades many investigations have demonstrated better oxygenation in hy-
poxic and ventilator treated patients, when treated in the prone position. 24, 28, 39, 50, 57, 73, 87, 100, 112, 159. 
Several investigations have shown more homogenous ventilation / perfusion ratios in prone com-
pared to supine position during mechanically ventilation 7, 99, 129. Perfusion and ventilation are more 
uniform in prone compared to supine position most likely depending on several factors discussed 
above. In the upright lung, Wests zonal model explains the gravity-influenced relationship, and 
therefore posture, between the intravascular hydrostatic pressures and the vertical height of the 
lung. In zone 1 the regional pulmonary arterial pressure (Ppa) is lower then the alveolar pressure 
(Palv) which results in no blood flow in the capillaries surrounding the alveoli. In zone 2 Ppa is 
above but pulmonary venous pressure (Pv) below Palv which results in an increasing vertical gradi-
ent in blood flow down this zone. In zone 3 Ppa > Pv > Palv resulting in maintained blood flow but 
decreased alveolar size 162. Several investigators in recent studies with high resolution techniques 
have confirmed an increased blood flow to dependent regions, due to the vertical pressure gradient, 
in upright position 70, 84, 119. Glenny showed 1999 that gravity explained 25% of the blood flow het-
erogeneity in upright baboons, but only 7% and 5% in the supine and prone postures respectively 
51. It should be kept in mind that in supine position, left atrial pressure is 10 cm H2O in healthy 
subjects, resulting in an extension of zone 3 to 10 cm above the center of the left atrium, which in-
cludes most of the lung height in prone and supine position. However, positive pressure ventilation 
might induce zone 2 conditions also in horizontal posture. Therefore the posture has limited effect 
on ventral-to-dorsal distribution of blood flow in prone and supine postures 118. When analysing 
results from investigations of regional pulmonary perfusion distribution indifferent postures, it is 
important to relate alterations in perfusion distribution to changes in tissue redistribution 118, 124. 
During the last decades the Seattle group has shown convincing data that the anatomical structure 
with fractal branching of the vascular and bronchial tree is the most important determinant of 
distribution of ventilation and perfusion 52, 55, 66. The structure of the vascular tree is suggested to 
explain 64% of the more homogenous PBF distribution in the prone position 7. These findings do 
not exclude coexisting differences in regional vasoreactivity of importance for regulation of pul-
monary perfusion. 
Could the optimized ventilation/perfusion matching in prone position reflect an adaptive evolution-
ary mechanism from the quadruped stage? Structure as well as regional vasoreactivity in the lung 
might have developed during millions of years to counteract the effect of gravity on ventilation/
perfusion distribution.
Introduction
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Aims
General aims
The majority of ventilator treated patients in intensive care units, suffering from Acute Lung 
Injury, ALI, improve gas exchange when turned prone. The overall purpose of this thesis was 
to reach new knowledge of importance for better understanding of mechanisms behind the 
improved gas exchange in prone position. The final goal was to explore new knowledge of 
possible use to improve treatment of patients with life-threatening lung disease in intensive 
care. 
Specific aims were to find out if:
- expression of mRNA for endothelial nitric oxide synthase (eNOS) is different in ven-
tral and dorsal lung regions in humans (I) 
- Ca2+-dependent and Ca2+-independent NOS activity is different in ventral and dorsal 
lung regions in humans (I)
- lung perfusion in ventral and dorsal lung regions is influenced by inhibition of NO 
synthesis (I)
- production of NO, in pigs, is different in ventral and dorsal lung regions (II)
- endothelium dependent mediators like acetylcholine and bradykinin act differently on 
ventral and dorsal pulmonary arteries in pigs (II)
- eicosanoids are involved in regulation of regional pulmonary perfusion in healthy hu-
mans (III)
- inhibition of prostaglandin synthesis decrease shunt fraction in the lungs during one-
lung ventilation for thoracic surgery (IV)
Aims
22
Regional Pulmonary Vasoreactivity
23
subjects, mAteriALs And methods
The methods have been described in detail in paper I-IV. Below follows a description of the meth-
ods more in general.
Table 2. Methods, total number of patients, volunteers and animals are given. Types of 
investigational methods are shown
Paper No.of No.of No.of
No Methods Investigation Patients Volunteers Animals
      
I SPECT Effect of NOS-inhibition on pulmonary perfusion in different body postures in healthy humans 9
I PCR eNOS mRNA 13
I, II Citrulline assay Ca2+-dependent NOS-activity 21 18
II Experimental organ bath Vasoreactivity 20
III SPECT
Effect of prostacyclin inhalation and COX-
inhibitionon pulmonary perfusion in different 
body postures in healthy humans
19
IV Clinical trial Effect of COX-inhibition on pulmonary perfusionduring hypoxia 32   
Subjects
Patients 
Altogether 53 patients were studied. In paper I there were 9 males and 12 females with mean age 
69 years (range 41-92) subjected to lung biopsies. All 21 were investigated by analysis of NOS 
activity, 13 of those were also investigated by analysis of eNOS mRNA. In paper IV there were 
11 men and 21 females with mean age 65 (range 36-81). They were all scheduled for lung surgery 
because of diagnosed or suspected pulmonary malignancy. Exclusion criterias were occurrence 
of other pulmonary disease or use of corticosteroids, acetyl salicylic acid or non-steroidal anti-
inflammatory substances. 
Volunteers
Altogether 28 non-smoking healthy volunteers participated. In paper I there were 5 males and 4 
females, mean age 31 years (range 23-47) and in paper III there were 9 males and 10 females, 
mean age 29 years (range 21- 45) studied. 
Animals
In paper II twenty pigs specially breaded for research, weighing 18.5-22.5 kg were studied. They 
were 18-22 weeks old.
Subjects, Materials and Methods
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Investigational methods
Real time polymerase chain reaction (PCR) for mRNA eNOS quantification (paper I)
Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany) and quantified by 
spectrophotometry. Two micrograms of total RNA were used for cDNA synthesis. Approximately 
50 ng of cDNA was amplified by real time polymerase chain reaction using primers and probes as 
described in (Table 3). Samples were analyzed in duplicate, and polymerase chain reaction amplifi-
cation was correlated against a standard curve. eNOS mRNA expression was quantified in relation-
ship to mRNA expression of β-actin, selected as a housekeeping gene.
Citrulline assay for NOS-activity (paper I and II)
The conversion of l-(U-14C) arginine to l-(U-14C) citrulline was used for measurement of NOS 
activity as previously described (paper I, II) 97, 133. The analysis was performed in the presence 
or absence of the calcium chelator ethyleneglycol-bis-(aminoethyl ether)-N, N-tetra acetic acid 
(EGTA) to differentiate between Ca2+ -dependent and Ca2+ -independent NOS activity. 
Organ bath experiments for vasoreactivity studies in isolated pulmonary arterial ring prep-
arations (paper II)
During anesthesia with spontaneous breathing the porcine heart and lungs were harvested, imme-
diately chilled in ice-cold physiological salt solution (PSS) and dissected on ice. Preparations of 
vascular rings from ventral and dorsal porcine pulmonary arteries were mounted vertically between 
two stainless steel hooks. The hooks were attached by silk sutures and arranged vertically between 
a stationary hook and a force transducer in 25 ml organ bath in PSS at +4◦C. The organ bath was 
continuously aerated with 5% CO2 in oxygen. The isometric tension generated in the vessel rings 
was continuously recorded on a multi channel Grass polygraph. Ring preparations were given an 
initial isometric load of 5 mN. The PSS temperature was raised to +37◦C over 60 minutes and the 
rings were then equilibrated for another 60 minutes before start of the experiment.
Sub maximal contraction was achieved with norepinephrine 10-6 M and cumulative dose-response 
curves for bradykinin, acetylcholine and nitroprusside were studied. NO-mediated relaxations were 
inhibited with L-NMMA, while diclofenac was used to inhibit possible prostacyclin mediated re-
laxations. The antagonism by L-NMMA or diclofenac was reversed by L-arginine and prostacyclin 
respectively.
Table 3 Target primers  and probes used for real-time 
polymerase chain reaction
Target Gene  Sequences (5’–3’)
eNOS   Primer forward GCAACGCTACCACGAAGACAT
 Primer reverse CGGCTTGTCACCTCCTGG
 Probe TCGGGCTCACGCTGCGCA
β-Actin   Primer forward CTGGCTGCTGACCGAGG
 Primer reverse GAAGGTCTCAAACATGATCTGGGT
 Probe CCTGAACCCCAAGGCCAACCG
Definition of abbreviation: eNOS = endothelial nitric oxide synthase.
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SPECT-single photon emission computed tomography for pulmonary perfusion or ventila-
tion studies (paper I and III)
Regional lung blood flow was investigated using macro aggregates of albumin labelled with radio-
active technetium 99mTc 134. Regional ventilation was marked using Technegas, a dispersion of ultra 
fine carbon particles labelled with 99mTc 25. All SPECT images were obtained with a three-headed 
gamma camera equipped with high resolution low-energy collimators. SPECT scans were per-
formed in 90 projections during 360◦ rotation with an examination time of 20 minutes. A 128x128 
matrix was used, giving a spatial resolution of 3.5 mm/pixel, for data acquisition and reconstruc-
tion. 
SPECT data analysis: 
3D images representing perfusion distribution were reconstructed from every acquisition per-
formed. To be able to distinguish the effects of an intervention between two acquisitions a subtrac-
tion procedure was done to “eliminate” the disturbing activity from the former image. Corrections 
for attenuation were performed 29.
In paper I perfusion distribution was analysed using rectangular volumes of interest (VOI)-width 
=18 mm and length = lung dimension in ventral–dorsal direction. Volumes were defined on the 
interface between the apical and mid and the mid and basal third of the right lung (Fig 2B). They 
were divided in two equal parts (ventral/dorsal) and their perfusion was expressed in percent of that 
in the entire VOI.
!
!
Figure 2. A) Design of study for SPECT analysis of pulmonary perfusion. Tracer administration 
and NO synthase inhibitor administration are indicated. 
B) Frontal view of apical and basal sections of SPECT image planes. Rectangular volumes of 
interest (VOI) were defined on the interface of the apical and mid third (apical section), and 
the mid and basal third (basal section) of the right lung. The VOI has a width of 18 mm and 
a length corresponding to the depth of the right lung. The VOI was divided in two equal parts 
(ventral/dorsal) and activity in each part is presented as a percent of the entire VOI.
A
B
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In paper III perfusion distribution was reconstructed in coronal sections from a 128x128 matrix, 
giving a spatial resolution of 3.5mm/pixel ( Fig 3B).The average activity deposition from ventral 
to dorsal in both supine and prone position was calculated. Activity data were collected by dividing 
the area under activity distribution curve in 20 sections, each 5% of the ventro-dorsal length. In 
order to perform inter-individual comparisons the average activity distribution was normalized to 
the length of the lung from ventral to dorsal. 
SPECT 1 after an intravenous injection of macro aggregates (50 MBq) illustrates perfusion under 
basal conditions. In paper I, perfusion distribution during NOS inhibition was obtained by subtract-
ing SPECT 2 data from SPECT 3, which was performed after the second injection of macro ag-
gregates (100 MBq). SPECT 2 was used to exclude any change in shape of basal activity. SPECT 
1 and SPECT 2 were not significantly different, which made subtraction analysis possible (Fig. 2A 
) In paper III, SPECT I illustrates basal conditions and SPECT 2 conditions after intervention, i.e. 
inhalation of iloprost or infusion of diclofenac (Fig. 3A).
Figure 3. A) Protocol outline for the iloprost inhalation experiment (upper panel) and the diclofenac infu-
sion experiment (lower panel). Blood samples for arterial bloodgases were taken every 10 min. Blood pres-
sure and heart rate were registered every 5 min. For the ventilation SPECT procedure, see the upper panel. 
Instead of using an injection of 99mTc-labelled macro-aggregated human albumin (MAA), the volunteers 
inhaled a gas mix containing 99mTc-labelled ultra-fine carbonaceous particles for 1 min.
B) Lateral view with coronal sections of SPECT image planes.
Ventral
Dorsal
A
B
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Clinical investigation with shunt calculations during unilateral hypoxia (paper IV)
During thoracic surgery with one-lung ventilation unilateral alveolar hypoxia appears followed by 
a right to left shunt. The shunt fraction was investigated during pharmaceutical intervention. For 
sampling of mixed venous blood a thermo dilution catheter was placed in a pulmonary artery via 
the right internal jugular vein. Arterial blood gases were collected via a radial arterial line. Hemo-
dynamic variables as continuous cardiac output, invasive systemic and pulmonary blood pressures, 
heart rate and gas exchange data were registered. 
Shunt fraction was calculated using the formula proposed by Riley et al. 130. Qs/Qt = (Cc´O2-CaO2) 
/ (Cc´O2-CvO2). The Cc´O2 is approximated with CAO2 calculated according to the following for-
mula CAO2 = 1.39 x Hb + PAO2 x 0.23 where PAO2 = FIO2 (PB-PH2O) - PACO2 (FIO2 + (1- FIO2) 
/ RQ. (RQ = respiratory quotient. For a mixed diet assumed to be 0.8)
Study protocols
The study designs for the SPECT investigations are shown in (paper I and III) (Fig 2, Fig 3).
Pharmaceutical interventions
NO synthesis inhibition was achieved with NG-monomethyl-L-arginine (L- NMMA) and the ef-
fect was verified by measurements of exhaled NO by chemiluminescence’s according to American 
Thoracic Society guidelines 9 (Paper I)
Prostaglandin synthesis inhibition was obtained with the non-selective cyclooxygenase inhibitor 
diclofenac 152 (Paper III). The inhibiton of prostacyclin synthesis was controlled with plasma 
analyses of 6-keto-prostaglandin1Fα, a stable metabolite of prostacyclin 105.
Inhalation of a prostacyclin analogue Iloprost (Ilomedin®) was performed with a micro proces-
sor controlled ultrasonic nebulizer (Optineb®-ir).The systemic uptake was controlled with plasma 
analyses of 6-keto-prostaglandin1Fα, a stable metabolite of prostacyclin.
Anesthesia
Patients
All patients scheduled for lung surgery were premedicated with morphine intramuscularly (paper 
I) or diazepam 5-10 mg orally (paper II) and anesthetized with propofol 1-2 mg kg-1, fentanyl 0.1 
mg, glycopyrron 0.2 mg and midazolam 1-2 mg after application of a thoracic epidural catheter at 
level Th5-6. A radial catheter was placed for continuous blood pressure measurements and arterial 
blood samples. Neuromuscular block was achieved with atracurium 0.5 mg kg-1 followed by en-
dobronchial intubation with a left-sided double lumen tube, size 37 CH for women and 39 CH for 
men. The correct position of the tube was confirmed by bronchoscopy, initially in supine and later 
in lateral decubitus position. Anaesthesia was maintained with propofol infusion 5-6 mg kg-1 h-1. 
An epidural infusion with bupivacain 5 mg /ml (paper I)/chirocaine 2.5 mg/ml (paper II) + suf-
entanyl 1 microgram/ml of 4-6 ml/h was started after a test dose of 4 ml bupivacaine 5 mg/ml with 
adrenalin 5 microgram/ml was evaluated. Mean arterial pressure (MAP) was maintained within 
30% of baseline values by administration of crystalloids and if necessary intermittent injections of 
2-4 micrograms norepinephrine. 
Mechanical ventilation was performed by using volume controlled ventilation with a Servo Venti-
lator (paper I) or a Draeger Julian Ventilator (paper IV) at FIO2 of 0.6 or higher if deemed. Arte-
Subjects, Materials and Methods
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rial blood gases were sampled from a radial catheter and the ventilator was set to achieve normal 
PaCO2 values. The I:E ratio was set to 1:2. In paper I there was no PEEP applied, in paper IV 
PEEP of 5 cm H2O was applied.
Volunteers
There were no sedatives used in the studies (paper I and III). The volunteers were awake and 
spontaneously breathing.
Animals
After pre-medication with ketamine hydrochloride 500 mg intramuscularly anesthesia with pento-
barbital sodium 25-30 mg kg-1 was induced. When there was no reaction to painful stimuli, biop-
sies were taken from ventral and dorsal lung regions during spontaneous breathing, frozen within 
1 minute in liquid nitrogen and stored in – 80◦C. Then the heart and lungs were removed and the 
animals were exsanguinated.
Statistics
Data in the text and tables are presented as means ± SD or median and 25th and 75th quartiles. Statis-
tical analysis was performed using SPSS for Windows. Statistical significance was tested according 
to Student’s t-test (paper I, III), Wilcoxon rank sum test (paper III) or Mann-Whitney non para-
metric U-test (paper IV) for paired and unpaired data. Two way analysis of variance for repeated 
measures was used to compare related data (paper I, paper III). Linear regression analysis was 
used to investigate correlations between different factors (paper IV). Chi-square and Fisher’s exact 
tests were used to analyse differences in number of subjects needing increased FIO2 in the different 
groups (paper IV). P-values < 0.05 were considered significant. In paper III, differences with 95% 
confidence intervals not intersecting with zero were considered significant. 
Ethical considerations
All studies were approved by ethical committees and in paper I and III approvals by radiation 
protection committee were obtained. Written consent was obtained from all subjects in paper I, 
III and IV. 
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resuLts
The results have been presented in detail in paper I-IV, and below follows a description of the find-
ings more in general.
Differences in vasoreactivity between ventral and dorsal lung regions with reference 
oxide. (Paper I, II)
Humans: mRNA expression for eNOS was twice as high in dorsal compared to ventral lung tissue 
in humans. P< 0.05 (Fig. 4A).
The Ca2+-dependent NOS activity was significantly higher (1.5 times) in dorsal compared to ventral 
human lung tissue (Fig. 4B).
Animals: The relaxing potency of acetylcholine and bradykinin, both endothelium dependent va-
sorelaxants acting via NO-release from vascular endothelium, was higher in isolated sub-maxi-
mally contracted porcine pulmonary arterial ring preparations from dorsal compared to ventral 
lung regions. Sodium nitroprusside, an endothelium independent NO-donor, was equally potent in 
relaxing dorsal and ventral isolated pulmonary arterial rings (Fig. 5).
The Ca2+-dependent NOS activity was 1.4 times higher in dorsal compared to ventral porcine lung 
tissue. P< 0.05 (Fig. 6).
Figure 4 A) Expression of mRNA for eNOS in ventral and dorsal lung tissue. Human lung eNOS mRNA 
levels are illustrated as relative units between the expression of eNOS mRNA and the housekeeping gene 
β-actin. Differences between the eNOS expression levels in dorsal and ventral parts of the lung were 
evaluated by Wilcoxon rank sum test for paired groups. (*=P<0.05, n=13). 
B) NOS activity in ventral and dorsal lung tissue. Activity of nitric oxide synthase in human lung speci-
mens obtained at surgery. The activity was determined in ventral (filled bars) and dorsal (open bars) 
specimens from the lower lobe in the presence and absence of 1.8 mM Ca2+. (*=P<0.05, n=21). 
A B
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Figure 5. Porcine pulmonary artery. Cumulative dose–
response curves for vasorelaxing agents on submaximal 
contractions to norepinephrine (10–6 M) in dorsally (open 
symbols) and ventrally (filled symbols) located porcine pul-
monary arteries. There were significantly greater relaxation 
responses in dorsal than ventral pulmonary arteries to the 
endothelium-dependent vasodilators acetylcholine (10–7–10–5 
M) (P < 0.05) (A) and bradykinin (10–10–10–7 M) (P < 0.001) 
(B). There were no significant differences in relaxation to the 
endothelium-independent vasodilator nitroprusside (10–7–10–5 
M) (C). n = number of different animals.
Figure 6. Porcine lung. Nitric oxide synthase (NOS) activity 
determined by citrulline assay in ventral and dorsal lung tis-
sue. The activity was determined in ventral (filled bars) and 
dorsal (open bars) biopsies from the lower parts of the lung 
in the presence and absence of 1.8 mM Ca2+. *P < 0.05, n = 
18.
NOS-inhibition, regional pulmonary perfusion and arterial oxygenation in vivo, 
healthy humans (Paper I) 
Volunteers: In the supine position, NOS-inhibition with L-NMMA redistributed regional pulmo-
nary perfusion from dorsal dependent lung regions to ventral pulmonary parts (Fig.7). Dorsal per-
fusion decreased from 56 to 52% and ventral perfusion increased correspondingly from 44 to 48%. 
In the prone position, however, there was no redistribution of regional pulmonary blood flow de-
tected after NOS-inhibition (Fig. 8). 
There were no differences in arterial oxygenation after NOS-inhibition by L-NMMA in neither 
supine nor prone positions in healthy humans.
There was a well-tolerated 10% increase in systemic arterial pressure and 19% decrease in heart 
rate during NOS-inhibition with L-NMMA. There were no significant differences in heart rate or 
blood pressure during the NOS-blockade due to posture (Fig. 9).
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!Figure 7. SPECT image of pulmonary perfusion before and after NOS inhibition. SPECT acquisition in a 
healthy human volunteer before (a) and after (b) administration of the NO synthase inhibitor L-NMMA iv. 
A horizontal projection is shown with the ventral lung regions facing upwards and the dorsal downwards. 
The subject was placed in the supine position throughout the procedure, and the basal parts of the lungs are 
shown. R=right lung. 
Figure 4. Regional pulmonary perfusion in supine and prone positions. Distribution of pulmonary blood flow 
is determined by SPECT in healthy human volunteers, studied at two different occasions in prone (n=8) and 
supine positions (n = 9), respectively. The relative distribution was determined for the ventral (filled bars) 
and dorsal (open bars) regions of the lungs before and during intravenous infusion of the NO synthase inhi-
bitor L-NMMA. At the first row, relative blood flow distribution in apical sections is shown and at the second 
row in basal sections. In the left column, data from supine positions are demonstrated, and in the right co-
lumn, data from prone positions are shown. (Statistical significance in the figure is indicated for differences 
between control conditions and in the presence of L-NMMA for ventral and dorsal VOIs, respectively; *p < 
0.05, **p < 0.01.)
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Figure 9. Effects by L-NMMA on exhaled NO, blood pressure, and pulse rate (healthy human 
volunteers in prone and supine positions). Summary of effects of intravenous infusion of the NO 
synthase inhibitor L-NMMA on exhaled nitric oxide (FENO ), arterial systolic (Syst) and diastolic 
(Diast) blood pressures, and heart rate (n = 17).
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Differences in regional pulmonary perfusion and arterial oxygenation with ref-
erence to prostaglandins in healthy humans. (Paper III)
Decreased prostacyclin levels:
In healthy humans there were no significant differences in regional pulmonary perfusion in ventro-
dorsal directions measured with SPECT after non-selective COX-inhibition (Fig.10). Neither arte-
rial oxygenation, heart rate nor blood pressure differed between control and diclofenac groups.
Increased prostacyclin levels: 
Arterial oxygenation: After inhalation of the synthetic prostacyclin analogue iloprost there was a 
decrease in arterial oxygenation which was of the same degree in both prone and supine positions; 
from 13.7 ± 1.4 kPa to 10.9 ± 2.1 kPa (P < 0.01) in supine and from 14.2 ± 0.5 kPa to 11.7 ± 1.7 kPa 
in prone position (P < 0.01, Fig 2 pekIII).
Changes in PaO2 were normalized 30 minutes after termination of the iloprost inhalation (Fig.11). 
Perfusion distribution: Iloprost inhalation induced an augmentation of blood flow in the dependent parts 
in both supine and prone position with a significant decrease in arterial oxygenation (Fig.12).
Ventilation distribution: After iloprost inhalation in the supine position, there was a significant 
change in the ventilation distribution from dependent to non-dependent lung regions.
Hemodynamic parameters: There was a transient increase in heart rate and decrease in arterial 
pressure during the iloprost-inhalation, normalized 8 min after termination of the inhalation. At 
the time when pulmonary perfusion distribution was measured by SPECT and the PaO2 was di-
minished, heart rate and blood pressure were completely normalized. The concentration of 6-keto-
prostaglandin F1α was not altered at the time the radioactive tracer was injected and trapped in the 
pulmonary capillaries.
Figure 10. Blood flow as a function of % ventral-to-dorsal distance in supine and prone positions before and 
after infusion of 75 mg diclofenac. The plots demonstrate the normalized mean values±SD for the vertical 
lung sections, each 5% of the total distance along a ventral-to-dorsal axis, n=10.  A) Perfusion distribution 
in the supine position, control (open circles) and after diclofenac infusion (filled circles). B) Perfusion 
distribution in the prone position, control (open circles) and after diclofenac infusion (filled circles). The 
edge effect (underestimation of radiotracer concentration at the lung periphery) causes blood flow per 
section to be underestimated at the extremes of the ventral-to-dorsal distance.
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Figure.11. Effects by iloprost inhala-
tion on PaO2 in healthy volunteers in 
prone (open circles) and supine (fil-
led circles) positions. PaO2 decreased 
during inhalation of iloprost in both 
supine and prone positions (P<0.01). 
There was no significant difference bet-
ween the effect of iloprost in the supine 
and the prone position.
Figure 12. Blood flow as a 
function of % ventral-to-
dorsal distance in supine 
and prone positions before 
and after inhalation of 20 μg 
iloprost. The top row: the 
plots demonstrate normali-
zed mean values±SD for the 
vertical lung sections, each 
5% of the total distance 
along a ventro-dorsal axis, 
n=9. The first column shows 
the perfusion distribution in 
the supine position (A) con-
trol (open circles) and after 
iloprost inhalation (filled 
circles). The second column 
shows the perfusion distri-
bution in the prone position 
(B) control (open circles) 
and after iloprost inhalation 
(filled circles). The edge ef-
fect (underestimation of ra-
diotracer concentration at 
the lung periphery) causes 
blood flow per section to be 
underestimated at the extre-
mes of the ventral-to-dorsal 
distance. The bottom row 
displays the differences sec-
tion by section between the 
regional perfusion distribution along the ventro-dorsal axis before and after iloprost inhalation in supine 
(C) and prone (D) positions. The lines show mean differences (filled squares) between blood flow with 
iloprost and control, low and high 95% confidence intervals (open squares), respectively. Confidence in-
tervals that do not intersect with zero indicate a significant difference between drug and control. Perfusion 
increased in dependent regions and decreased in non-dependent regions in both the supine and the prone 
position. Note the different pattern in differences between drug and control in the supine as compared with 
the prone position.
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Differences in pulmonary perfusion with reference to 
prostaglandins during regional hypoxia in vivo. (Paper IV)
In regional pulmonary hypoxia during one-lung ventilation (OLV) for thoracic surgery, the di-
clofenac treated group showed a significant reduction of the shunt fraction compared to the placebo 
group. After 15 minutes of OLV the shunt increased 3.1 times compared to base line measurements 
in the placebo group, while the increase was just 2.2 times in the diclofenac group (P > 0.043, 
Fig.13).
There were no differences between groups in patient characteristics or preoperative conditions (Ta-
ble 4). During investigations there were no significant differences in peroperative bleeding, serum 
creatinine, respiratory  or hemodynamic variables between the groups (Table 5, Table 6). Shunt 
fraction in the placebo group increased from 12 (10, 14) % (median (25th,75th percentiles)) during 
TLV to 39 (24, 44) % and 38 (31, 46) % after 15 and 30 minutes after OLV respectively. In the 
diclofenac group shunt fraction increased from 12 (12, 14) % at TLV to 28 (16, 36) % and and 30 
(18, 35) % after 15 and 30 minutes of OLV respectively. Shunt fraction was significantly improved 
in the diclofenac group compared with the placebo group after 15 minutes of OLV (P = 0.043), but 
not after 30 minutes of OLV (P = 0.068) (Fig.13). This lack of statistical significance might have 
been due to the smaller number of patients (n = 20) evaluated due to prior initiation of surgical 
vessel ligation at this time point. During left-sided surgery (LSS), shunt fraction was significantly 
improved at both 15 (P = 0.020) and 30 min (P = 0.036) of OLV (Fig.14 A). During right-sided 
surgery (RSS) reductions of shunt fractions due to diclofenac were not prominent and did not reach 
statistical significance (Fig.14 B).
Plasma concentrations of 6-keto-prostaglandin F
1α
 were [228 (164, 469 pg/ml)] in the placebo 
group and [73 (47, 94)] in the diclofenac group (P = 0.003) 60 minutes after start of the diclofenac 
infusion, i.e. at OLV 2. 
In order to maintain SpO2 above 90% FIO2 had to be increased above 0.6 in 10 patients (4 RSS 
and 6 LSS) in the placebo group and in 5 patients (all RSS) in the diclofenac group (P = 0.077). 
Preoperative PO2 and PCO2 values were similar in patients requiring increased FIO2 compared with 
those who did not. In the entire patient material PaO2/FiO2 ratios and P (A-a) O2 differences were 
not changed after diclofenac treatment (Table 5). In patients subjected to left-sided lung surgery, 
however, P (A-a) O2 values in the diclofenac treated patients at 15 minutes of OLV were signifi-
cantly lower than in the placebo group (P < 0.029, Fig. 15).
Table 4.  Patient demographics. 
 placebo (n=16) diclofenac (n=16)  P
Age (yr) 65 (28-76) 71 (36-81) 0.10
Females 9 12
BMI (kg m-2) 24.2 (20, 25) 26.7 (22.9, 28.3) 0.11
Hemoglobin (g l-1) 128 (120, 144) 137 (128, 143) 0.48
Albumin (g l-1) 38 (35, 40) 38 (37, 41) 0.35
Creatinine (g l-1) 72 (60, 93) 65 (58, 84) 0.30
PaO2 kPa 10.4 (10.1, 10.8) 10.4 (8.9, 12.8) 0.96
PaCO2 kPa 5.4 (5.1, 6.0) 5.1 (4.9, 5.6) 0.10
FEV1 (liters s
-1) 2.6 (1.9, 3.0) 2.1 (1.8, 2.7) 0.16
% of predicted FEV1 84 85
VC (liters) 2.9 (2.5, 4.1) 2.8 (2.6, 3.5) 0.8
% of predicted FVC 82 87
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Figure 14 A) Shunt fraction (%) in patients subjected to left-sided thoracic surgery, placebo (unfilled) 
and diclofenac groups (filled boxes). Measurements were performed after induction of anesthesia (supine 
position) and in lateral decubitus position during two-lung (TLV) and one-lung ventilation (OLV) and finally 
after restoration of TLV. Measurements were registered at 15 min intervals. The shunt was significantly 
larger in the placebo group at OLV2 (P = 0.020) and at OLV3 (P = 0.036); n = 8). Data are presented as 
median, quartiles and 5th and 95th percentiles.
B) Shunt fraction (%) in patients, subjected to right-sided thoracic surgery, placebo (unfilled) and diclofenac 
groups (filled boxes). Measurements were performed after induction of anesthesia (supine position) and in 
lateral decubitus position during two-lung (TLV) and one-lung ventilation (OLV) and finally after restoration 
of TLV. Measurements were registered at 15 min intervals. The shunt was not significantly different between 
placebo and diclofenac (P = 0.642) at OLV2 and (P = 0.667) at OLV3; n = 8). Data are presented as 
median, quartiles and 5th and 95th percentiles.
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Figure 13. Shunt fraction (%) in all patients, left and right thoracic surgery, pooled data for the 
placebo (unfilled) and diclofenac groups (filled boxes). Measurements were performed after induction 
of anesthesia (supine position), in lateral decubitus position during two-lung (TLV) and one-lung 
ventilation (OLV) and finally after restoration of TLV. Measurements were registered at 15 min intervals. 
The shunt was significantly larger in the placebo group at OLV2 (P = 0.043; n = 16). Data are presented 
as median, quartiles and 5th and 95th percentiles. 
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Table 5. Gas exchange data, pooled material
PvO2 PaO2 PaCO2 P (A-a) O2 PaO2/FIO2 % Shunt
TLV supine p p p p p p
placebo 5.8 (5.4, 6.0) 25.7 (19.4, 33.7) 5.4 (5.2, 5.6) 18.5 (13.0 ,23.8) 49.5 (40.0, 61.2) 12 (10, 14)
diclofenac 5.8 (5.5, 6.1) ns 25.2 (18.8 ,34.4) ns 5.0 (4.5, 5.4) ns 22.0 (13.0, 24.0) ns 46.5 (38.0, 61.2) ns 12 (10, 14) 0.850
       lateral
placebo 5.8 (5.4, 6.5) 24.4 (21.2, 30.7) 5.4 (5.2, 5.8) 19.0 (11.2, 24.5) 45.5 (39.5, 60.2) 12 (9, 14)
diclofenac 6.0 (5.9, 6.3) ns 26.3 (21.0 , 34.5) ns 5.3 (5.0, 5.8) ns 17.0 (12.0, 19.0) ns 50.5 (43.0, 62.8) ns 13 (8, 15) 0.636
OLV 5 min
placebo 5.5 (5.3, 5.8) 15.6 (10.2, 24.2) 5.6 (5.0, 5.9) 28.0 (24.2, 35.5) 30.0 (16.2 ,41.5) 21 (16, 37)
diclofenac 5.9 (5.4, 6.3) ns 15.8 (12.5, 26.6) ns 5.2 (4.8, 5.4) ns 27.0 (18.2, 31.5) ns 29.0 (24.0, 48.2) ns 25 (14, 30) 0.854
       15 min
placebo 5.0 (4.8, 5.5) 9.0 (8.3, 10.0) 5.3 (4.9, 5.9) 39.0 (31.0, 51.0) 16.0 (12.0, 22.0) 39 (24, 44)
diclofenac 5.1 (4.9, 5.8) ns 9.3 (8.5, 22.8) ns 5.0 (4.8, 5.2) ns 32.0 (27.0 ,41.0) ns 17.0 (15.0, 31.0) ns 28 (16, 36) 0.043
       30 min
placebo 5.0 (4.8, 5.5) 9.3 (8.6, 9.9) 5.4 (5.0, 5.9) 37.0 (34.0, 58.0) 15.0 (12.0, 17.0) 38 (31, 46)
diclofenac 5.1 (5.0, 6.1) ns 10.4 (8.4, 19.2) ns 5.1 (4.7, 5.2) ns 36.0 (31.0, 48.0) ns 16.0 (13.0, 35.0) ns 30 (18, 35) 0.068
after lig.
placebo 5.0 (4.8, 5.5) 11.2 (9.8, 15.2) 5.4 (4.8, 5.7) 39.0 (30.8, 53.2) 19.0 (17.0, 22.8) 26 (21, 32)
diclofenac 5.5 (5.1, 5.8) ns 17.5 (10.7, 23.8) ns 4.9 (4.6, 5.1) ns 28.0 (21.8, 39.0) ns 28.5 (16.8, 42.8) ns 22 (14, 29) 0.198
TLV lateral
placebo 5.5 (5.2, 6.0) 25.0 (20.8, 32.4) 5.3 (4.9, 5.7) 23 (14.0, 27.0) 48.0 (38.0, 58.0) 14 (8, 17)
diclofenac 5.6 (5.4, 6.1) ns 27.2 (24.2, 31.6) ns 5.2 (4.8, 5.5) ns 15.0 (9.2, 21.2) ns 51.0 (47.2, 64.2) ns 9 (7, 14) 0.092
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Figure 15. P(A-a)O2 during left-sided (A) and right-sided (B) thoracotomy in placebo (unfilled symbols) and 
diclofenac treated patients (filled symbols). Measurements were performed after induction of anaesthesia 
(supine position) and in lateral decubitus position during two lung (TLV) and one-lung ventilation (OLV) and 
finally after restoration of TLV. Measurements were registered at 15 min intervals. During left thoracotomy 
P(A-a)O2 values were significantly different between placebo and diclofenac treated at OLV2 (P = 0.024), 
OLV3 (P = 0.027) and after restoration of TLV (P = 0.032; n = 8). 
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Table 6. Hemodynamic data, pooled material
HR MAP CVP MPAP CI % Shunt
TLV supine p p p p p p
placebo 72 (56, 75) 74 (61, 90) 15 (12, 17) 24 (18, 27) 2.2 (1.8, 2.4) 12 (10, 14)
diclofenac 62 (56, 73) ns 66 (60, 81) ns 16 (12, 18) ns 24 (19, 26) ns 2.2 (1.4, 3.2) ns 12 (10, 14) 0.850
       lateral
placebo 68 (55, 74) 72 (64, 89) 16 (13, 18) 23 (21, 27) 2.3 (2.0, 2.6) 12 (9, 14)
diclofenac 67 (59, 75) ns 72 (68, 92) ns 16 (13, 20) ns 26 (19, 31) ns 2.6 (2.1, 3.0) ns 13 (8, 15) 0.636
OLV 5 min
placebo 72 (68, 81) 74 (65, 90) 14 (13, 17) 24 (23, 27) 2.4 (2.0, 2.8) 21 (16, 37)
diclofenac 73 (64, 78) ns 77 (72, 88) ns 15 (12, 19) ns 24 (20, 30) ns 2.5 (2.1, 2.8) ns 25 (14, 30) 0.854
       15 min
placebo 73 (66, 80) 70 (62, 78) 17 (14, 18) 26 (23, 27) 2.4 (2.1, 2.6) 39 (24, 44)
diclofenac 73 (62, 75) ns 70 (64, 83) ns 15 (12, 16) ns 24 (22, 29) ns 2.6 (2.3, 2.8) ns 28 (16, 36) 0.043
       30 min
placebo 76 (71, 86) 67 (66, 90) 16 (14, 19) 25 (24, 29) 2.7 (2.1, 3.1) 38 (31, 46)
diclofenac 70 (65, 82) ns 82 (64, 95) ns 15 (13, 16) ns 25 (21, 29) ns 2.8 (2.3, 3.1) ns 30 (18, 35) 0.068
after lig.
placebo 71 (64, 82) 72 (67, 81) 16 (13, 17) 26 (23, 28) 2.5 (2.2, 2.8) 26 (21, 32)
diclofenac 69 (61, 82) ns 86 (78, 92) ns 15 (13, 16) ns 26 (21, 30) ns 2.5 (2.1, 2.9) ns 22 (14, 29) 0.198
TLV lateral
placebo 70 (60, 75) 72 (70, 88) 15 (11, 18) 26 (21, 29) 2.6 (2.0, 2.8) 14 (8, 17)
diclofenac 67 (62, 82) ns 78 (65, 86) ns 14 (11, 17) ns 24 (22, 29) ns 2.4 (2.1, 2.9) ns 9 (7, 14) 0.092
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 discussion
The highlights of this thesis are that endogenous NO synthesis is involved in regional regulation 
of pulmonary vascular tone and that NO production is higher in dorsal compared with ventral lung 
regions in humans. SPECT images in volunteers, before and after NOS inhibition, verify the func-
tional importance of these findings.
The higher degree of NO production in the dorsal parts of the lungs provide the final link in search-
ing for an answer to questions raised by a study 1986, where Beck and Rehder 14 demonstrated 
higher vascular conductance in dorsocaudal compared to ventrocephaled regions in isolated dog 
lungs. The results contribute to better understanding of the more uniform perfusion distribution 65, 
80, 104, 147, 155 and V/Q ratios 7, 99, 129 with improvement in oxygenation demonstrated when patients 
with ALI and ARDS are turned into prone position 24, 39, 100. 
Are there differences in regional pulmonary vasoreactivity to nitric oxide? 
An important determinant for regional distribution of pulmonary blood flow has, during the recent 
decades, been suggested to be the fractal anatomy of the vascular tree 49, 52, 55, 66, 129. However, vas-
cular trees are not passive structures. Regional differences in smooth muscle vascular tone may 
modify the influence of an “intrinsic structure”, as we have demonstrated in these series. First, we 
have shown differences in vasoreactivity between isolated porcine arterial rings from dorsal and 
ventral pulmonary arteries to the endothelial-dependent vasorelaxants, acethylcholine and brady-
kinin, acting via nitric oxide release (paper II). Second, the mRNA expression of eNOS is higher 
in dorsal compared with ventral human lung tissue. Ca2+-dependent NOS-activity, as measured by 
citrulline assay is higher in dorsal lung regions in two different species, humans and pigs. Finally, 
NOS-inhibition by L-NMMA in vivo redirected blood from dorsal to ventral lung regions in the 
supine position (paper I). In paper II, we could also define the endothelium as the site of interest 
for the differences in vasoreactivity in the pulmonary arteries, by investigating the effect of an en-
dothelium-independent NO-donor, sodium nitroprusside. Sodium nitroprusside, acting directly on 
the smooth muscle cell, showed no differences in vasorelaxing potency between dorsal and ventral 
porcine arterial rings, in contrast to the endothelium-dependent vasodilator acetylcholine. 
Our findings are consistent with earlier in vitro studies. Beck and Rehder demonstrated in 1986 a 
higher vascular conductance in dorsocaudal than in ventrocephalad regions of isolated perfused 
dog lungs 14. Later, Pelletier et al. showed a more pronounced endothelium-dependent vascular 
relaxation in dorsal compared to ventral isolated equine pulmonary arterial rings to a number of 
substances acting via the cGMP / NO pathway 111. 
Whether the increased NOS activity in dorsal lung regions, found in our study, is a primary or 
secondary phenomenon cannot be fully answered by this study. NO production in vivo is regulated 
by different factors. Shear stress caused by high blood flow may result in enhanced NO synthesis 
in dorsal lung regions 120. This might indicate that the observed higher Ca2+-dependent NOS activ-
ity described in this study is a secondary phenomenon and not the cause of higher blood flow in 
dorsal regions in the supine position. NOS activity was analyzed in vitro under standardized condi-
tions, for example, equal amounts of enzyme substrate, L-arginine, indicating that constitutional 
enzyme activity was higher in dorsal lung regions. The NOS activity analysed in our study was 
not influenced by shear stress because the analysis was made in vitro, not in blood vessels in vivo. 
Ca2+-independent, inducible NOS activity did not differ between ventral and dorsal tissue samples. 
Furthermore, expression of mRNA for eNOS was higher in dorsal regions. Taken together, our 
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results strongly suggest a difference in eNOS mRNA expression and Ca2+-dependent NOS activity 
under basal conditions, leading to differences in vasoreactivity in dorsal and ventral lung regions.
To summarise, the findings in paper I and II add evidence to a regulatory role for nitric oxide in 
regulation of regional pulmonary blood flow distribution. 
Can differences in regional pulmonary vasoreactivity play a role in regional 
lung blood flow distribution with reference to posture?
A dominant dorsal lung perfusion in the supine position 8, 77 and more uniform perfusion in the 
prone position has been shown in previous studies in humans and animals during spontaneous 
ventilation 65, 101, 104, 155. These earlier findings were obtained with the use of various techniques such 
as radiospirometry 13 and SPECT in humans 108 and microspheres in animals 65, 155. The agreement 
between different species using a variety of techniques indicate a true description of physiologic 
conditions, which is further strengthened in this study. It should be kept in mind that the present 
SPECT method does not measure perfusion per se but the image produced by radioactive micro-
spheres trapped in capillaries. Also, it is important to keep in mind the confounding effects by 
the compressible nature of lung parenchyma when evaluating perfusion redistribution caused by 
changes in posture. Normalisation for perfusion / alveolus or density instead of unit volume must 
be considered 118, 123. The tracer technique is, on the other hand, well established 13, 92 and allows for 
relative comparisons, as conditions are stable between the acquisitions. NOS inhibition by L-NM-
MA in the supine position redirected blood from dorsal to ventral lung regions (Fig.7, Fig. 8). Most 
probably this is caused by a relatively larger change in the vascular tone of dorsal pulmonary ves-
sels as compared with ventral vessels while supine. However, it is surprising that NOS inhibition 
while prone did not result in a parallel redirection of pulmonary blood flow. Hence, body position 
may affect the response to L-NMMA. It is not likely that this is due to technical factors concerned 
with the SPECT technique or the infusion of the NOS inhibitor.
This observation may invoke the assumption that the mechanical change, supine to prone, causes a 
different stretching of the pulmonary vasculature that changes the response to L-NMMA. Increased 
exhalation of NO during ventilation with positive end expiratory pressure in rabbits has been sug-
gested to be caused by a stretch-dependent regulation of pulmonary NO formation in animals 1, 116. 
The greater compression of dependent lung regions in supine 4, 124 results in regional hypoxia 7  which 
may induce HPV in dorsal regions. The higher NO production in dorsocaudal regions, found in this 
study, will attenuate HPV 46. Hence, inhibition of NO production by L-NMMA would enhance HPV 
leading to redistribution of pulmonary blood flow. A weaker regional HPV due to less tissue com-
pression in prone position may explain the lack of effect by L-NMMA in prone posture. However, 
the difference in response to NOS inhibition between supine and prone position could not be fully 
explained in this study, and further investigations need to confirm and clarify this point. 
The increased vascular conductance in dorsal lung regions, demonstrated by Beck and Rehder, could 
be explained by anatomical differences such as number of vessels and branching differences. Fractal 
vascular trees and perfusion heterogeneity in iso-gravitational planes suggest an anatomic structural 
basis for regulation of regional pulmonary blood flow 49, 55, 66, 129. The Seattle group 7 demonstrated in 
2004, by in vitro microsphere technique in anesthetized, mechanically ventilated pigs, that pulmo-
nary structure was responsible for around 65% of total blood flow heterogeneity and around 75% of 
total ventilation heterogeneity. There was a posture-mediated relatively small redistribution of blood 
flow primarily oriented along the ventrodorsal axis, with increased blood flow to the dependent re-
gions, more pronounced in the supine position. Hence, gravity contributes to regulation of regional 
pulmonary perfusion, but has to be considered as a secondary determinant 51, 53.
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However, these observations do not exclude differences in regional pulmonary vasoreactivity to 
nitric oxide, found in this thesis, as an important contributor to the increased vascular conductance 
in dorsal lung regions and more uniform pulmonary perfusion distribution seen in the prone posi-
tion. 
Are there differences in regional pulmonary vasoreactivity to prostacyclin?
Regional pulmonary vasoregulatory differences could include other signal systems than those me-
diated by NO / guanylylcyclase / cGMP pathway (paper I, II). The prostaglandin system, for 
instance, involves substances acting via the adenylyl cyclase / cAMP pathway. Inhalation of the 
synthetic prostacyclin analogue iloprost has been shown to have selective pulmonary vasorelaxing 
effects 12, 105, 107. In this thesis, we could not confirm any regional differences in effects on regional 
pulmonary basal vascular tone to an exogenous prostacyclin analogue. Iloprost inhalation in both 
supine and prone positions increased perfusion in dependent lung regions, i.e., enhanced the ef-
fect of gravity (Fig.12). Non-selective COX-inhibition did not redistribute blood flow in either 
prone or supine position, which further supported the suggestion that the eicosanoid system is not 
involved in regulation of regional pulmonary perfusion in normal lungs (Fig.10). However, the 
limited number of observations cannot exclude an action by endogenous eicosanoids. 
The observed effects in this study might be explained by an uneven gravity dependent drug distri-
bution. The iloprost particle size used in the present study, should guarantee a drug deposition in 
peripheral airways 135, 150. Ventilation distribution was also studied in a subset of the volunteers in 
supine position. Iloprost, which is known yo have bronchorelaxant effects 143, redistributed ven-
tilation towards ventral, that is, non-dependent lung regions. This argues against that an uneven, 
preferentially dependent distribution of inhaled iloprost would explain the perfusion redistribution 
towards dependent lung regions in both supine and prone positions.
Surprisingly, iloprost inhalation in these healthy volunteers caused a decrease in arterial oxygena-
tion in both the supine and prone position (Fig.11). The PBF redistribution towards dependent 
regions regardless of body position, and the gas redistribution in opposite direction in supine posi-
tion, contributed to increased V/Q mismatch with impaired arterial oxygenation. Other possible 
mechanisms behind the changed oxygenation might be altered cardiac output by systemic drug 
effects. However, the administration method and dose of iloprost presently used has been shown 
to selectively dilate pulmonary vasculature 105, 107. Although heart rate and blood pressure increased 
during the iloprost inhalation, they were completely normalized when pulmonary perfusion dis-
tribution was measured by SPECT and at the same time PaO2 was diminished. Furthermore, the 
fact that the concentration of 6-ketoprostaglandinF1α was not altered at the time the radioactive 
tracer was injected and trapped in the pulmonary capillaries strongly indicates that the effect by 
iloprost on pulmonary perfusion distribution was mediated via local receptors in the lungs and not 
indirectly via systemic effects.
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Vasoactive drugs, hypoxic pulmonary vasoconstriction and regional pulmo-
nary perfusion. 
The effects of iloprost inhalation in healthy humans are not consistent with the findings in several 
clinical studies where patients with ALI and ARDS have been treated with inhalations of prosta-
cyclin or its analogues and have shown improved oxygenation 35, 153. In experimental lung injury 
models enhanced pulmonary vascular resistance has been demonstrated due to either damaged en-
dothelial function or hypoxic vasoconstriction or a combination of the two 33, which might explain 
the favourable effects of prostacyclin treatment in severe lung disease. These observations confirm 
that underlying pathophysiology, the clinical conditions or the presence of positive pressure ven-
tilation with concomitant effects on pre-existing vascular tone are of crucial importance for the 
effects of vasoactive substances 58. 
In the present studies, COX-inhibition on healthy humans (paper III) did not influence regional 
blood flow distribution, while in the hypoxic situation (paper IV) during one lung ventilation for 
thoracic surgery, there was a marked reduction of shunt fraction due to redistributed blood flow 
after administration of a non-selective COX-inhibitor during left-sided thoracic surgery. Other fac-
tors like anesthetic agents 15, 16, 20, 78, 79, 89, 109, 126, cardiac output 42, hypercapnia 38, 43 and pulmonary 
blood flow 37 known to interact with HPV and shunt fraction were similar in the placebo and di-
clofenac groups. These factors were therefore less likely to be responsible for the observed differ-
ences between the groups. 
It is well documented in animal and human studies that HPV is modulated by endothelial derived 
vasoactive substances 46, 138. When lung pathology and hypoxia is at hand, the effect of COX-
inhibition might be different compared to normal physiological conditions 35, 58, 69, 105, 153, 165. During 
one-lung ventilation the low alveolar oxygen tension activates HPV in the non-ventilated lung with 
a redistribution of 40-50 % of the blood flow to the ventilated lung 18. Our findings in humans are 
consistent with many in vitro and in vivo animal studies, showing decreased shunt fraction and 
improved arterial oxygenation after administration of non-selective COX-inhibitors when regional 
hypoxia is induced 6, 59, 138. 
Interestingly, there was a posture related difference in the response to prostaglandin-inhibition 
during one lung ventilation in the lateral decubitus position. Alterations of lung perfusion are also 
known to be influenced by changes in body position 7, 30, 104, 119, 129. However, the smaller effect on 
the shunt fraction by COX inhibition in patients with right-sided surgery was interesting and dif-
ficult to explain. In the lateral decubitus position the dependent lung has a reduced lung volume 
due to anesthesia, muscular paralysis and compression by the mediastinal and abdominal contents 
103, all of which contribute to atelectasis 145 and a decrease in compliance 82. Hence, both pulmonary 
perfusion and ventilation will be compromised, more marked when the smaller left lung is depend-
ent 30. This leads to a lower regional Po2 and therefore a higher grade of HPV in the ventilated 
lung when the left lung is dependent 30, which might counteract the blood flow redistribution from 
the non-ventilated lung. In addition, HPV is more effective in diverting blood flow and reducing 
hypoxemia when the hypoxic region is a small fraction of the total lung 88. Thus, it is possible that 
the effect of COX inhibition on blood flow redistribution due to HPV is more effective when the 
larger right lung is dependent. Hence, body position cannot be ruled out as contributory factor to 
the observed difference in effect by COX-inhibition between left and right thoracotomy.
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It is of great importance to understand the causative mechanisms to impaired gas exchange in 
patients with lung pathology to be able to find new treatment strategies. There exists an extensive 
amount of research concerning the many passive factors determining PBF distribution like gravity 
and posture 119, 125, 162, vascular structure 49, 52, 55, 66 and lung mechanics 103, 114. Some of these factors 
can be used in clinic practice by changing body posture and by optimizing ventilation characteris-
tics. 
In this thesis we have investigated the role of the vasoactive endothelial-derived factors, NO and 
prostacyclin, in regulation of regional PBF during normal and hypoxic conditions. The findings in 
the present thesis, that there are differences in vasoreactivity between dorsal and ventral pulmonary 
regions due to higher endothelial production of NO in dorsal pulmonary arteries might have clinical 
implications. Selective inhibition of eNOS activity in order to redistribute PBF from the dependent 
dorsal regions in the supine position may become a valuable tool in the treatment of patients with 
ALI or ARDS. The blood flow redistribution may lead to a more homogeneous ventral-to-dorsal 
perfusion distribution which in turn may improve arterial oxygenation due to optimised ventilation/
perfusion matching. 
The findings in paper IV that the use of a non-selective COX-inhibitor during one-lung ventilation 
decreases shunt during left-sided thoracic surgery has interesting clinical implications. First, the 
patients subjected to thoracic surgery are often elderly with inherent lung diseases and thus might 
benefit from preoperative COX-inhibition to reduce the risks for severe perioperative hypoxia dur-
ing one-lung ventilation. Especially in minimally invasive thoracic procedures, requiring a well-
collapsed lung, where CPAP to the non-ventilated lung is inapplicable, COX-inhibition may be 
advantageous 22, 26. Second, non-selective COX-inhibition may offer an easy way to minimize the 
exposure to high FIO2, minimizing absorption atelectasis 
41 and decreasing the risk of oxygen toxic-
ity and inflammatory activation in the ventilated lung 74, 83, 122. 
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concLusions 
Based on the results in this thesis it was concluded that:
•	 expression of mRNA for endothelial nitric oxide synthase (eNOS) in humans is higher in 
dorsal than ventral lung regions (I).
•	 Ca2+-dependent NOS activity is higher in dorsal compared with ventral human lung 
regions (I). 
•	 in pigs Ca2+-dependent NOS activity is higher in dorsal than in ventral lung regions (II).
•	 relaxation of porcine pulmonary arteries by endothelium dependent vasoactive mediators 
such as acetylcholine and bradykinin is more potent in dorsal than in ventral arteries (II).
•	 the endothelium independent NO donor sodium nitroprusside relaxes, in pigs, ventral and 
dorsal pulmonary arteries equally (II).
•	 in supine volunteers, pulmonary blood flow is redirected from dorsal to ventral lung 
regions during NOS inhibition (I). 
•	 iloprost inhalation redistributes pulmonary blood flow to dependent lung regions 
regardless of posture while ventilation is redirected towards non-dependent lung regions 
in supine position leading to decreased arterial oxygen tension in healthy humans (III).
•	 non-selective inhibition of cyclooxygenase (COX) by diclofenac does not affect 
pulmonary perfusion distribution in healthy humans (III)
•	 non-selective inhibition of cyclooxygenase (COX) by diclofenac reduces shunt fraction 
during one-lung ventilation for left sided thoracic surgery, accompanied with improved 
gas exchange, showed by a decrease in alveolo – arterial oxygen tension difference. (IV). 
generAL concLusions
Based on the results in this thesis it was concluded that there exist differences in pulmonary 
vasoreactivity between ventral and dorsal lung regions for the endothelial derived mediator 
nitric oxide, at different levels such as gene transcription and enzyme activity, adding new 
knowledge contributing to logical explanations to variations in gas exchange between supine 
and prone positions. 
The eicosanoid system is involved in regional perfusion distribution during regional hypoxia. 
This knowledge may improve treatment strategies for patients with acute lung injury and 
acute respiratory distress syndrome and for patients subjected to one-lung ventilation during 
thoracic surgery.
Conclusions
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